IND Swift has informed that as per the Company’s Code of Conduct for prevention of Insider Trading read with Regulation 4 of the Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015, and notification no. NSE/CML/2019/11 and LIST/COMP/01/2019-20 issued respectively by NSE and BSE on 2nd April, 2019, further read with SEBI circular no. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated 05.08.2023, the Trading Window of the Company is closed for all Promoters, members of the Promoter Group, Directors, KMPs, designated person(s), connected person(s)/insiders and their immediate relatives as covered under the Code, for dealing in securities of the Company, with effect from 1st October, 2024 and will remain closed till 48 hours after the declaration of Unaudited Financial Results for the Quarter ending September 30, 2024.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |